The estimated net worth of Dr. David M. Altshuler is at least $76,925,820 as of 15 Nov 2024. He owns shares worth
$10,079,977 as insider, has earned $28,835,843
from insider trading and has received compensation worth at least
$38,010,000 in Vertex Pharmaceuticals Incorporated.
What is the salary of David M. Altshuler?
Dr. David M. Altshuler salary is $1,810,000 per year
as Executive Vice President of Global Research & Chief Scientific Officer in Vertex Pharmaceuticals Incorporated.
How old is David M. Altshuler?
Dr. David M. Altshuler is 60 years old, born in 1965.
What stocks does David M. Altshuler currently own?
As insider, Dr. David M. Altshuler owns shares in one company:
Executive Vice President of Global Research & Chief Scientific Officer
25,813
$390.5
$10,079,977
What does Vertex Pharmaceuticals Incorporated do?
Vertex Pharmaceuticals Incorporated, a biotechnology company, engages in developing and commercializing therapies for treating cystic fibrosis. The company markets SYMDEKO/SYMKEVI, ORKAMBI, and KALYDECO to treat patients with cystic fibrosis who have specific mutations in their cystic fibrosis transmembrane conductance regulator gene; and TRIKAFTA for the treatment of patients with CF 6 years of age or older who have at least one F508del mutation. Its pipeline includes VX-864 for the treatment of AAT deficiency, which is in Phase 2 clinical trial; VX-147 for the treatment of APOL1-mediated focal segmental glomerulosclerosis, or FSGS, and other serious kidney diseases which is in Phase 2 clinical trial; VX- 880, treatment for Type 1 Diabetes which is in Phase 1/2 clinical trial; VX-548, a NaV1.8 inhibitor for treatments of acute, neuropathic, musculoskeletal pain which is in Phase 2 clinical trial; and CTX001 for the treatment severe SCD and TDT which is in Phase 3 clinical trial. The company sells its products primarily to specialty pharmacy and specialty distributors in the United States, as well as specialty distributors and retail chains, and hospitals and clinics internationally. It has collaborations with Affinia Therapeutics, Inc.; Arbor Biotechnologies, Inc.; CRISPR Therapeutics AG.; Kymera Therapeutics, Inc.; Mammoth Biosciences, Inc.; Moderna, Inc.; Obsidian Therapeutics, Inc.; and Skyhawk Therapeutics, Inc.; as well as Ribometrix, Inc.; Genomics plc; Merck KGaA; Darmstadt, Germany, and X-Chem, Inc. Vertex Pharmaceuticals Incorporated was founded in 1989 and is headquartered in Boston, Massachusetts.
Dr. David M. Altshuler has made 138 insider trades between 2004-2024, according to the Form 4 filled with the SEC. Most recently he sold
15 units of VRTX stock worth $7,178 on 15 Nov 2024.
The largest trade he's
ever made was exercising 56,250 units of VRTX stock
on 16 Jan 2018. As of 15 Nov 2024
he still owns at least 25,813 units of VRTX stock.
